2012
Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)—a double blind, randomized clinical trial
Banai S, Finkelstein A, Almagor Y, Assali A, Hasin Y, Rosenschein U, Apruzzese P, Lansky AJ, Kume T, Edelman ER. Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)—a double blind, randomized clinical trial. American Heart Journal 2012, 165: 234-240.e1. PMID: 23351827, PMCID: PMC4637940, DOI: 10.1016/j.ahj.2012.10.023.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionLate lossCoronary interventionDiabetes mellitusPrimary efficacy end pointBare metal stent implantationEnd pointSystemic innate immunityEfficacy end pointPlacebo-controlled trialPrimary end pointAcute coronary syndromeStent late lossMetal stent implantationSingle intravenous bolusVascular injury sitesAverage late lossBaseline monocyteLiposomal alendronateCoronary syndromePlacebo groupStudy drugCoronary narrowingOverall cohortPrespecified subgroups
1999
Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion
Teirstein P, Mann J, Cundey P, Schechter E, Jacobs W, Grines C, Stagaman D, Lansky A, Hultquist M, Kusnick B, Heuser R, Kleinert H, Popma J. Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion. The American Journal Of Cardiology 1999, 83: 1623-1628. PMID: 10392865, DOI: 10.1016/s0002-9149(99)00163-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsCerebral HemorrhageChronic DiseaseCoronary AngiographyCoronary DiseaseDose-Response Relationship, DrugFemaleGraft Occlusion, VascularHeparinHumansInfusions, IntravenousMaleMiddle AgedPlasminogen ActivatorsRecombinant ProteinsSaphenous VeinUrokinase-Type Plasminogen ActivatorConceptsSaphenous vein graftsR-UKStudy drugVein graftsMyocardial infarctionNon-Q-wave myocardial infarctionPrimary study end pointSaphenous vein graft occlusionHigh-dose armStudy end pointLife-threatening bleedingVein graft occlusionHigh-dose groupDuration of infusionRecombinant urokinaseAcceptable success rateIntracerebral bleedPercutaneous revascularizationFinal angiogramGraft occlusionRecanalization rateAngiographic analysisHuman kidney cellsAllergic reactionsLow dose